Black Diamond Therapeutics Announces First Patients Dosed in Phase 1 Clinical Trial Expansion Cohorts Evaluating BDTX-1535 in Patients with Intrinsic Driver and Acquired Resistance EGFR Mutation Positive Non-Small Cell Lung Cancer

In this article:
Black Diamond Therapeutics, IncBlack Diamond Therapeutics, Inc
Black Diamond Therapeutics, Inc
Advertisement